

Studienliste Onkologie

| Studie | Entität | Stadium | Linie | Titel | LKP | EudraCT-Number |
|--------------|------------|-----------------------|-------|---|---|----------------|
| aktiv | | | | | | |
| FIRE 4.5 | Kolorektal | metast. | first | Randomised study to investigate FOLFOXIRI plus cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer | Prof. Dr. Volker Heinemann , München | 2015-004849-11 |
| PANAMA | Kolorektal | metast. | first | Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer | PD Dr. med. Dominik Paul Modest, Berlin | 2012-005422-30 |
| INTEGA | Magen | lokal inop. / metast. | first | Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastatic EsophagoGastric Adenocarcinoma | PD Dr. med. Alexander Stein, Hamburg | 2017-000624-10 |
| ALPACA | Pankreas | metast. | first | Induction Treatment with nab-Paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and nab-Paclitaxel/Gemcitabine or Continuing Application of nab-Paclitaxel/Gemcitabine: A Randomized Phase II Study | Prof. Dr. Frank Kullmann, Klinikum Weiden | 2014-004086-24 |
| CONKO 007 | Pankreas | lokal inop. | first | Randomisierte Phase-III-Studie zum Stellenwert einer Radiochemotherapie nach Induktionschemotherapie beim lokal begrenzten, inoperablen Pankreaskarzinom: Chemotherapie gefolgt von Radiochemotherapie im Vergleich zur alleinigen Chemotherapie | Prof. Dr. Rainer Fietkau Universitätsklinikum Erlangen | 2009-014476-21 |

Studienliste Onkologie

| | | | | | | |
|--------------------------------|----------------------|---|--------|---|---|----------------|
| NEONAX | Pankreas | operabel | first | Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer | Prof. Dr. med. Thomas Seufferlein, Ulm | 2013-005559-34 |
| PREDICT | Pankreas | fortgeschritten | second | Second-line therapy with Nal-IRI after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy | Prof. Dr. med. Manfred P. Lutz, Saarbrücken | 2016-005147-17 |
| IMPORTANCE | Kopf-Hals | metast. | second | Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma | Dr. Dorota Lubgan, Erlangen | 2017-002122-20 |
| SEATTLE | Lunge, Kopf-Hals | fortgeschritten | second | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | Prof. Dr. med. Patrick Michl, Halle | 2017-005076-26 |
| MARGINALZONEN-LYMPHOM REGISTER | Marginalzone lymphom | | | Nicht-interventionelles prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonen-Lymphomen | Dr. med. Peter Koch, Münster; Prof. Dr. C. Buske, Ulm | |
| PANTAX Ib | Pankreas | lokal inop, fortgeschr. oder metastasiert | first | An open-label phase Ib prospective clinical trial to investigate safety, tolerability and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer patients. | Prof., DMSc, Morten Ladekarl, Aalborg, Dänemark | 2020-002627-11 |
| ELDERLY AIO KRK 0117 | Kolorektal | lokal inop, fortgeschr. oder metastasiert | first | Aflibercept and 5-FU vs. FOLFOX as 1st line treatment option for elderly or frail elderly patients with metastatic colorectal cancer | Prof. Dr. med. Ralf-Dieter Hofheinz, Mannheim | 2017-000329-11 |

Studienliste Onkologie

| | | | | | | |
|------------------------|-------------------------|--|------------------------|---|---|----------------|
| MIRATI 849-010 | Kolorektal | fortgeschritten | on or after first line | A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy | - | 2020-004048-27 |
| AIO 18.2 | Rektum | fortgeschritten | first | Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure | Prof. Dr. Ralf-Dieter Hofheinz, Heidelberg | 2018-001356-35 |
| ANTONIO AIO-KRK-0220 | Kolorektal | operabel | first | Perioperative/Adjuvant atezolizumab with or without the immunomodulatory IMM-101 in patients with MSI-high or MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy | Prof. Dr. S. Kasper-Virchow, Essen | 2020-002715-21 |
| GOBLET | Pankreas/ Kolorektal | lokal inop, fortgeschr. oder metastasiert | first - third | A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers exploring treatment combinations with pelariciclib and atezolizumab | Prof. Dr. med. Dirk Arnold, Hamburg | 2020-003996-16 |
| BNT122-01 | Kolorektal | operabel | first | A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection | Scott Kopetz MD, Houston Texas, US | 2020-000451-12 |
| ESPAC-6 AIO-PAK.0121 | Pankreas | operabel | first | An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature | Prof. Dr. Dr. med. Markus W Büchler, Heidelberg | 2020-004906-79 |
| CIRCULATE AIO-KRK-0217 | Kolorektal | operabel | first | Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung (CIRCULATE) AIO-KRK-0217 | Prof. Dr. Gunnar Folprecht, Dresden | 2018-003691-12 |

Studienliste Onkologie

| | | | | | | |
|---------------------------|-------------------------------------|---|--------------|--|--|----------------|
| RACE | Gastroösophagealer Übergang | operabel | first | Neoadjuvant Radiochemotherapy versus Chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ) RACE-trial: A randomized phase III joint study of the AIO, ARO and DGAV | Prof. Dr. med. Ralf-Dieter Hofheinz, Mannheim | 2018-001728-20 |
| BERING-CRC | Kolorektal | metast. | second | Encorafenib and cetuximab in patients with metastatic, BRAFV600E-mutated, colorectal carcinoma: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria | Prof. Dr. med. Sebastian Stintzing, Berlin (wissenschaftlicher Leiter) | 2018-003691-12 |
| COUP-1 | MZL | operabel/ inoperabel | first/second | Copanlisib and Rituximab in Marginal Zone Lymphoma Patients | Prof. Dr. Christian Buske, Ulm | 2017-003150-16 |
| CP-MGAH22-06 Macro Genics | Magen + Gastroösophagealer Übergang | fortgeschritten, metastasiert (unbehandelt) | first | A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer | | 2019-004699-21 |
| LYNK-003 (MK-7339-003) | Kolorektal | inoperabel oder metastasiert | second | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003) | Prof. Reinacher-Schick, Bochum | 2019-000698-22 |